You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
阿斯利康(AZN.US)斥12億美元收購亙喜生物(GRCL.US)
中國細胞療法開發商亙喜生物(GRCL.US)宣布,已與阿斯利康(AZN.US)對其的收購提案達成最終協議。 此次擬議收購將進一步擴充阿斯利康公司的細胞療法管線,為其增添一款處於臨床階段、針對多種惡性血液腫瘤和自體免疫疾病的BCMA/CD19自體CAR-T細胞療法,以及專有的細胞療法FasTCAR生產技術平台。 亙喜生物股東將在交易完成時獲得亙喜生物普通股每股2美元,相當於每股美國存託股份(ADS)10美元的現金,外加亙喜生物普通股每股0.3美元 (相當於每股ADS 1.5美元)的不可交易的或有價值權益(CVR),包括CVR在內的總交易價值高達12億美元。 該交易預計將於今年第一季完成,仍要取決於慣例成交條件、監管部門的批准,以及亙喜生物股東的批准。如果交易完成,亙喜生物將成為私有化控股公司,其美國存託憑證將從納斯達克交易所退市。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account